Current Topics in Medicinal Chemistry - Volume 13, Issue 22, 2013

Tuberculosis (TB) is a serious public health issue, particularly in underdeveloped and developing countries. Furthermore the first-line anti-TB treatments were established over 40 years ago, multidrug-resistant Mycobacterium tuberculosis strains have been developed and the risk of coinfection with AIDS virus has highlighted this disease as a global emergency. The urgent need for more effective treatments against multidrug-resistant strains compatible with anti-AIDS drugs has prompted industries, governments and non-governmental agencies to pursue new drugs. In this study, we update the portfolio listed at Stop TB Partnership, present the biological activities as well as structure-activity relationship for these drugs and thoroughly discuss the synthetic methodologies used to produce these drugs.

The 1H-1,2,3-triazoles have been studied for many years as an important class of heterocyclic compounds and still attracting considerable attention due to their several application such as, organocatalyst, ionic liquid and broad range of biological activities, including several neglected diseases as tuberculosis. This review emphasizes the recent advances of these triazoles and their perspective in the development of new bioactive chemical entities against tuberculosis.

Worldwide, tuberculosis is the leading cause of morbidity and mortality due to a single bacterial pathogen, Mycobacterium tuberculosis (Mtb). The increasing prevalence of this disease, the emergence of multi-, extensively, and totally drug-resistant strains, complicated by co-infection with the human immunodeficiency virus, and the length of tuberculosis chemotherapy have led to an urgent and continued need for the development of new and more effective antitubercular drugs. Within this context, the L-histidine biosynthetic pathway, which converts 5-phosphoribosyl 1-pyrophosphate to L-histidine in ten enzymatic steps, has been reported as a promising target of antimicrobial agents. This pathway is found in bacteria, archaebacteria, lower eukaryotes, and plants but is absent in mammals, making these enzymes highly attractive targets for the drug design of new antimycobacterial compounds with selective toxicity. Moreover, the biosynthesis of L-histidine has been described as essential for Mtb growth in vitro. Accordingly, a comprehensive overview of Mycobacterium tuberculosis histidine pathway enzymes as attractive targets for the development of new antimycobacterial agents is provided, mainly summarizing the previously reported inhibition data for Mtb or orthologous proteins.

Tuberculosis is a severe infectious disease currently being treated with drugs that were developed more than 40 years ago. In recent years, the emergence of resistant Mycobacterium tuberculosis strains, as well as co-infection with the AIDS virus, has caused global concern about the evolution of the disease. Thus, the search for new drugs has become a necessity and a great challenge. Fluorine is a strategic element that is very useful in medicinal chemistry for its great influence on the biological activity of substances. This review highlights the importance of fluorinated molecules that are currently in clinical use or pre-clinical phases of development. Further, some substances in the prototype development stage are cited, which potentially represent future alternatives for the treatment of tuberculosis.